NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has been granted a license from California allowing the Australian firm to sell its BrevaGen breast cancer test in that state.

The Laboratory Field Services Unit of the California Department of Public Health has granted a license to Genetic Technologies' Australian-based laboratory, the firm said. The state represents about 11 percent of the total number of breast cancer incidents in the US with more than 25,000 new cases of breast cancer diagnosed annually, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.